

Alkylating agents			Plant products (cont)			Anti-metabolites (cont)		
Sulfur mustard	Nitrogen mustard/ 1) Meclorothamine	Nitrosourea	Uses: ttt of breast, ovarian & aids-related kaposi sarcoma.			2) Uracil mustard	MOA: inhibits the rate-limiting step during purine synthesis.	Uses: remission in leukaemia and breast cancer management.
is converted into episulfonium ion attacked by nucleophile from cells and becomes alkylated biopolymer.	Given IV. Becomes the unstable aziridinium ion and then gives alkylated biopolymer.	Streptoazocin	Signal transduction (PK) inhibitors			Alkylating agent.	Uses:	
			Imatinib mesylate	Sorafenib tosylate		MOA: Damages DNA that in take in uracil.	- with methotrexate for lymphocytic leukemia.	
			MOA: Competitive inhibition of TK--> inducing apoptosis or non-dividing cells.	MOA: Broad spectrum kinase inhibitor		Uses: Non-hodgkins lymphoma	- Immunosuppressive for UC, psoriatic arthritis, systemic lupus erythromatosis.	
			Uses: CML, GIST, acute lymphoblastic leukemia (+ve philadelphia chromosomes)	Uses: renal cell carcinoma and colon cancer			Allopurinol potentiates its effect by inhibiting its metabolism.	
			SE: thrombocytopenis, skin rash, N/V, pulmonary edema.	SE: Skin rash, HTN, fatigue, increased risk of bleeding & wound healing time.				
	2) Chlorambucil		Advantage: Orally administered, better patient tolerability.			Miscellaneous compounds		
	Relatively stable; given oral.		Disadvantage: Cardiotoxicity			Platinum complexes	Synthetic retinoid analog	
	Least toxic, long-acting.		Resistance to tyrosine kinase forms:			1) Cisplatin	1) Bexarotene	
	3) Cyclophosphamide		- Altering amino a' to stop binding			MOA: Cross-links DNA causing DNA conformational changes.	MOA: binds to activated retinoid X receptors in skin.	
	Active orally and parenterally.		- Increasing kinase levels			Uses: with bleomycin & vinblastine for metastatic testicular tumors.	Use: cutaneous T-cell lymphoma	
	Both sulfur and nitrogen mustard are converted into unstable 3-membered (onium) intermediates that they act by.		- Drug is substrate to efflux transporter, BCRP.			2) Carboplatin		
Plant products			Anti-metabolites					
Vinca alkaloids	Ixabepilone		Pyrimidine antimetabolites	Purine antimetabolites	Folic a' antimetabolites			
Include vincristine, vinblastine, vinorelbine, vinorelbine	semisynthetic amide analogue of the spindle poison, Epothilone B.		1) 5-FU	1) 6-MP	1) Methotrexate			
1) Paclitaxel (taxol)	Has lactam in its structure providing increased <i>in vivo</i> stability.		MOA: thymidylate synthase inhibitor or incorporated into RNA & DNA.	Is <i>in vivo</i> converted into 6-thionosinate.	MOA: dihydrofolate reductase inhibitor			
MOA: spindle poison inhibiting mitosis.	Uses: Metastatic breast cancer							



Immunotherapy/monoclonal antibodies

**Block	**Flag	**Deliver
1) Trastuzumab	1) Rituximab	1) Brentuximab vedotin
Blocks HER-2 receptors to stop growth.	chimeric (hybrid) monoclonal antibody.	Delivers chemotherapy drugs inside tumor cells.
2) Bevacizumab	Flag malignant B lymphocytes with CD20 receptor for the immune cells.	
Blocks VEGF--> no new blood vessels.	Use: Non-Hodgkins B-cell lymphoma.	
MOA: targeted therapy by selective binding on receptor to--**		

Antibiotics

Anthracyclines	Actinomycin
1) Doxorubicin HCl	1) Bleomycin
MOA: intercalates into DNA causing indirect inhibition of topoisomerase II--> decreased RNA & DNA synthesis.	Has multiple heterocyclic rings and cytotoxic glycosides.
SE: Cardiotoxicity, release of hydroxyl and superoxide radicals.	MOA: Fragmentation of DNA.
2) Doxorubicin HCl	2) Mitomycin C
Uses: Acute leukaemia, Hodgkins's disease	3 anti-cancer functional gps: Quinone + Aziridine + Carbamate.

Antibiotics (cont)

MOA: cross-links double helical DNA		
Unreactive in natural state--reduction--> Indol-hydroquinone (bifunctional alkylating agent)		
Hormones		
Testolactone	Tamoxifen	Letrozole
MOA: Aromatase inhibitor stopping estrogen synthesis from testosterone.	Non-steroidal agent with anti-estrogen properties.	MOA: Aromatase inhibitor
Uses: Breast cancer in post-menopausal women.	MOA: binds to estrogen receptors resulting in decreased DNA transcription.	Uses: locally advanced or metastatic breast cancer.
Uses: breast cancer in post-menopausal women.		

